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Abstract
We have identified a large expansion of an ATTCT repeat within intron 9 of ATXN10 on chromosome 22q13.31 as the genetic
mutation of spinocerebellar ataxia type 10 (SCA10). Our subsequent studies indicated that neither a gain nor a loss of
function of ataxin 10 is likely the major pathogenic mechanism of SCA10. Here, using SCA10 cells, and transfected cells and
transgenic mouse brain expressing expanded intronic AUUCU repeats as disease models, we show evidence for a key
pathogenic molecular mechanism of SCA10. First, we studied the fate of the mutant repeat RNA by in situ hybridization. A
Cy3-(AGAAU)10 riboprobe detected expanded AUUCU repeats aggregated in foci in SCA10 cells. Pull-down and co-
immunoprecipitation data suggested that expanded AUUCU repeats within the spliced intronic sequence strongly bind to
hnRNP K. Co-localization of hnRNP K and the AUUCU repeat aggregates in the transgenic mouse brain and transfected cells
confirmed this interaction. To examine the impact of this interaction on hnRNP K function, we performed RT–PCR analysis of
a splicing-regulatory target of hnRNP K, and found diminished hnRNP K activity in SCA10 cells. Cells expressing expanded
AUUCU repeats underwent apoptosis, which accompanied massive translocation of PKCd to mitochondria and activation of
caspase 3. Importantly, siRNA–mediated hnRNP K deficiency also caused the same apoptotic event in otherwise normal
cells, and over-expression of hnRNP K rescued cells expressing expanded AUUCU repeats from apoptosis, suggesting that
the loss of function of hnRNP K plays a key role in cell death of SCA10. These results suggest that the expanded AUUCU–
repeat in the intronic RNA undergoes normal transcription and splicing, but causes apoptosis via an activation cascade
involving a loss of hnRNP K activities, massive translocation of PKCd to mitochondria, and caspase 3 activation.
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Introduction
Spinocerebellar ataxia type 10 (SCA10) is an autosomal
dominant neurodegenerative disease presented with progressive
pancerebellar ataxia, leading to total disability [1–4]. Approxi-
mately 60% of the SCA10 patients also suffer from epilepsy with
complex partial seizures and generalized tonic-clonic seizures,
which become life-threatening due to development of status
epilepticus [3–5]. The disease-causing genetic mutation is a large
(up to 22.5 kb) expansion of a pentanucleotide, ATTCT, repeat
present within the ninth intron of the ATXN10 gene on
chromosome 22q13.31 [6].
In the last two decades, investigators identified a group of
diseases caused by expansions of short tandem repeats, also known
as microsatellite repeats. Most of these mutations involve unstable
trinucleotide repeats located in different regions of respective
genes. The roles of repeat expansion mutations in the pathogenic
mechanism of these diseases are diverse and complex [7,8].
However, in a simplistic view an expanded repeat in the coding
region produces an elongated tract of repetitive amino acid
residues with a gain of toxic function at the protein level, whereas
a triplet repeat expansion in 59- and 39-untranslated regions
(UTR) may result in an altered transcription level of the gene or a
production of toxic RNA transcript containing expanded ribonu-
cleotide triplets. Friedreich’s ataxia (FRDA) is the only known
disease caused by an expansion of an intronic trinucleotide repeat.
Typical FRDA mutations are large GAA repeats located in intron
1 of the FXN gene, which severely hinders the transcription of the
FXN gene, leading to the autosomal recessive phenotype [9].
SCA10 and myotonic dystrophy type 2 (DM2) are only human
diseases caused by non-trinucleotide microsatellite expansion
mutations although an insertion of a large pentanucleotide repeat
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DM2 the mutation is a large (up to 44 kb) expansion of CCTG
tetranucleotide repeat in intron 1 of the ZNF9 gene. Thus, it is an
interesting coincidence that non-trinucleotide mutations in DM2
and SCA10 are both large expansions located in an intron and
causing autosomal dominant phenotypes. In DM2, expanded
CCUG tetranucleotide repeat transcripts accumulate mostly in
nuclear foci, and sequestrate the muscleblind like 1 (MBNL1)
protein into the RNA foci [11,12]. The resultant depletion of
MBNL1 causes splicing dysregulation of a variety of RNA
transcritpts similar to DM1. Splicing misregulation is thought to
be the primary pathogenic mechanism in DM1 and DM2.
In SCA10 the number of ATTCT repeats ranges from 10 to 29
in normal individuals, and increases up to 4,500 in patients
[13,14]. The ATXN10 gene consists of 12 exons spanning
172.8 kb, and encodes ataxin 10, which contains two armadillo
repeats known to mediate protein-protein interaction. Knock-
down of ATXN10 by RNAi induces cell death in primary
cerebellar neurons [15], whereas over-expression of ATXN10
activates the mitogen-activated protein kinase cascade and
promotes neurite extension in PC12 cells [16]. While ATXN10 is
expressed in a wide variety of tissues, expression is especially strong
in brain, heart and muscle. Although these data suggest that ataxin
10 plays a role in neuronal survival and differentiation, the exact
function of ataxin 10 remains unknown. Thus, it is plausible that a
large expansion of the ATTCT repeat may interfere with the
transcription, like the GAA repeat expansion does in FRDA,
leading to a loss of function of ataxin 10. However, we recently
demonstrated that neither a gain nor a loss of the function of
ATXN10 is the primary pathogenic mechanism of SCA10 [17].
Analyses of SCA10 fibroblasts showed that the ATXN10 mRNA
levels remain unaltered in spite of the repeat expansion [6,17]. In
addition, transcription of the mutant alleles and post-transcrip-
tional splicing of the mutant ATXN10 transcript remain largely
unaltered in SCA10 patients [17]. Furthermore, homozygous
Atxn10 knockout (Atxn102/2) mice showed embryonic lethality
while heterozygous (Atxn10+/2) mice showed no phenotype [17].
Finally, a recent report described patients with balanced
translocation t(2;22)(p25.3:q13.31), in which the breakpoint of
chromosome 22q13.31 disrupted intron 2 of ATXN10 [18]. These
patients were totally asymptomatic, suggesting that haploinsuffi-
ciency of ATXN10 does not cause SCA10.
In the present study, we examine whether the expanded
AUUCU RNA repeat in the mutant ATXN10 transcript is the
principal pathogenic molecule capable of triggering neuronal
death in SCA10. We demonstrate that the expanded AUUCU
repeat within the spliced intron interacts with hnRNP K, and this
RNA-protein interaction results in loss of hnRNP K function,
translocation of Protein Kinase C d (PKCd) to mitochondria and
activation of apoptosis in SCA10 cells. Furthermore, we observe
that targeted inactivation of the mutant ATXN10 transcripts in
SCA10 cells significantly reduces mitochondrial translocation of
PKCd. Together, these results define a key pathogenic mechanism
of SCA10 and provide clues for potential therapeutic strategies.
Results
Mutant ATXN10 transcripts are accumulated as inclusion
aggregates in SCA10
We propose that the mutant ATXN10 transcripts containing
expanded AUUCU repeats contribute towards the SCA10
phenotype. To investigate whether the sub-cellular distribution
and fate of the mutant ATXN10 transcripts are altered, RNA FISH
analysis with a Cy3-(AGAAU)10 riboprobe was performed on
SCA10 fibroblasts containing ,2000 or ,1,000 ATTCT repeats
and on normal fibroblasts expressing the wild type ATXN10
transcripts containing 12 AUUCU repeats. The (AGAAU)10
riboprobe detected the presence of nuclear and cytoplasmic
aggregates in SCA10 fibroblasts (Figure 1A; arrows, also Figure
S1A; arrow), but not in normal fibroblasts (Figure 1B). These
aggregates observed in this and other Figures were resistant to
DNAse and disappear after RNAse treatment. Since our previous
study showed that the 9
th intron of the ATXN10 gene (66,421 bp)
encoding the expanded AUUCU repeats is spliced normally [17],
our present results imply that the intron 9 sequences are spliced
and partly translocated to the cytoplasm in SCA10 fibroblasts.
FISH with an anti-sense probe specific for exon 9 of the ATXN10
gene showed no significant binding in the same SCA10 fibroblasts
(data not shown), confirming that the aggregated AUUCU repeat
sequences are spliced from the mutant ATXN10 transcripts. These
findings suggest that intron 9 containing the expanded AUUCU
repeat is spliced out of the mutant ATXN10 transcripts, but
expanded AUUCU repeats within the spliced intron 9 are resistant
to degradation, and deposited as aggregates in nuclei and in
cytoplasm in SCA10 cells.
Ectopically expressed AUUCU repeats are accumulated as
distinct aggregates
We determined whether expanded AUUCU repeats alone are
sufficient to form aggregates. Untranslated ,500 AUUCU repeats
from a transgene (Figure 1C) were expressed in human
neuroblastoma Sy5y cells. The transgene is designed to express
an expanded ATTCT repeat within the rabbit b-globin intron
downstream of the human a-enolase promoter and upstream of the
LacZ reporter. Using RT-PCR analysis, we confirmed that the
AUUCU-repeat-containing the rabbit b-globin intron is spliced
from the transcript when the transgene is expressed in Sy5y cells
(data not shown). FISH analysis of the Sy5y cells expressing ,500
AUUCU repeats showed SCA10-like nuclear and cytoplasmic
aggregates (Figure 1D). However, under identical conditions,
aggregates were not detected in Sy5y cells expressing the lacZ
transcripts encoding shorter repeats (12 or 25 repeats) (data not
shown). FISH analysis of transfected normal human fibroblasts
expressing ,500 AUUCU repeats also showed SCA10-like
Author Summary
In an earlier study, we showed that the mutation of
spinocerebellar ataxia 10 (SCA10) is an enormous expan-
sion of a gene segment, which contains a tandemly
repeated 5-base (ATTCT) unit. Since SCA10 is the only
known human disease that is proven to be caused by 5-
base repeat expansion, it is important to learn how this
novel class of mutation causes the disease. We found that
the mutation produces an expanded RNA repeat, which
aberrantly accumulates in SCA10 cells and interacts with a
major RNA–binding protein. When we expressed expand-
ed RNA repeats or decreased the RNA–binding protein
level in cultured cells, either of these manipulations
produced a specific type of cell death that is associated
with a massive transfer of a key enzyme called protein
kinase C delta to mitochondria. We also showed that either
blocking the expanded AUUCU repeat or replenishing
hnRNP K rescues cells from the cell death induced by the
SCA10 mutation. Together, we conclude that the mutant
RNA inactivates hnRNP K and kills cells by triggering the
specific cell-death mechanism. Our data provide important
clues for therapeutic intervention in SCA10.
RNA Gain of Function in the Pathogenesis of SCA10
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data indicate that even when the expanded AUUCU repeat is
ectopically expressed, the intronic sequence is spliced from the
transcript of the transgene, becomes resistant to degradation, and
aggregates in nuclear and cytoplasmic foci in Sy5y cells.
We also determined whether transcripts with expanded
AUUCU sequences form similar aggregates in mouse brain.
Transgenic mouse lines using the construct described in Figure 1C
were generated. Repeat-primed PCR (RP-PCR) analyses of
genomic DNA from these mice showed the presence of expanded
ATTCT repeats (Figure 1E), and Southern analyses confirmed the
presence and integrity of ,500 ATTCT repeats (Figure 1F). The
(AGAAU)10 riboprobe detected distinct intracellular aggregates in
brains from 6-month-old (Figure 1G) and 3-month-old (Figure
Figure 1. Expanded AUUCU transcripts form discrete aggregates. (A) FISH on SCA10 fibroblasts encoding ,2,000 ATTCT repeats showing
multiple, bright RNA aggregates (arrow) in the nuclei, nuclear boundary and cytoplasm. (B) FISH on normal control fibroblasts hybridized with a Cy3-
labeled (AGAAU)10 probe. (C) Schematic drawing of the transgenic constructs including a human a-enolase promoter, 2
nd intron of rabbit b-globin
gene, LacZ gene, expanded ,500 ATTCT repeats cloned within the intron (or normal range of 12 repeats for control), and Bovine Growth Hormone
(BGH) polyA sequences. (D) FISH on Sy5y cells ectopically expressing intronic ,500 AUUCU repeats from the transgenic constructs shown in
Figure 1C. Figure showing the nuclear, perinuclear as well as cytoplasmic foci (arrow). (E) Ladder-PCR analysis of mouse genomic DNA showing the
presence of expanded ATTCT repeats, lane 1: Positive control from SCA10 patients; Lane 2: Transgenic mouse containing 12 ATTCT repeats, lane 3 &
4: Transgenic mouse encoding ,500 ATTCT repeats. (F) Southern blot of the XbaI-HindII digested genomic DNA from the transgenic F1 encoding
,500 ATTCT repeats (lane 2, 3). Lane 1: Wild-type control mouse DNA. Lane 2 and 3: Transgenic mice expressing ,500 ATTCT repeats. Southern blot
shows the presence of ,500 ATTCT repeats. A DNA fragment (,500 bp) of the 59 of the intron 9 of ATXN10 gene was used as the Southern probe. (G)
FISH on sagittal sections of the wild type (left panel) and transgenic mouse brain encoding ,500 AUUCU repeats (right panel). Bars represent 10 mm
in this and all other figures.
doi:10.1371/journal.pgen.1000984.g001
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Importantly, similar to the SCA10 cells, we observed a large
number of aggregates not only in the nucleus but also in the
cytoplasm, and they were more abundant in 6-month-old than 3-
month-old mice (Figure 1G and Figure S1C). The formation of
SCA10-like aggregates in these cells and transgenic mouse brains
confirms that the expanded AUUCU repeats are necessary and
sufficient to form nuclear and cytoplasmic aggregates. Moreover,
these large foci suggest that the expanded AUUCU-RNA repeats
may aggregate as insoluble RNA-protein complexes, as described
in other repeat expansion disorders [7,8].
Expanded AUUCU transcripts activate apoptosis
Light-microscopic analysis of the Sy5y cells expressing the ,500
AUUCU repeats showed a dramatic increase in cell death
(Figure 2A), whereas cells expressing normal-size repeats showed
virtually no cell death (Figure 2B). A TUNEL assay revealed that
more than 70% of cells expressing the ,500 AUUCU repeats
underwent apoptosis 48 hours after transfection (Figure 2A and
2C), while cells expressing 12 AUUCU repeats did not undergo
apoptosis (Figure 2B and 2C) (p,0.0001). Furthermore, caspase-3
activity was significantly higher in cells expressing ,500 AUUCU
repeats than in control cells (p,0.0001) (Figure 2D), suggesting
that the expanded AUUCU repeats activate caspase-3-mediated
apoptosis. We also observed that expression of ,500 AUUCU
repeats cause apoptosis in PC12 cells (Figure S2).
Expanded AUUCU RNA binds to heteronuclear
ribonuclear protein K (hnRNP K)
The distinct aggregates in SCA10 cells and transgenic mouse
brains led us to hypothesize that the expanded AUUCU repeat
RNA may interact with proteins, and that such interactions may
have pathogenic significance. We pulled down proteins from
mouse brain extracts using biotin-labeled expanded AUUCU
RNA repeats and analyzed them by SDS-PAGE (Figure 3A). The
unique protein that was reproducibly and repeatedly pulled down
(n=6) was identified by mass spectrometry as hnRNP K
(Figure 3A; arrow). hnRNP K contains three K-homology (KH)
domains that mediate its interactions with RNA and a K
interactive (KI) region with proline-rich docking sites important
for src homology domain binding. To establish the specificity of
the interaction of hnRNP K with AUUCU RNA, purified hnRNP
K was incubated with single-stranded (AUUCU)15 RNA and
extracted with buffers containing increasing salt concentrations.
The data show a significant affinity of hnRNP K with (AUUCU)15
RNA even in the presence of 250 mM NaCl; in contrast hnRNP
K is completely dissociated from the control RNA at significantly
lower (#100 mM) salt concentrations (Figure 3B). Thus, hnRNP
K can bind tightly to AUUCU repeats, in addition to the
consensus sequence, U(C3-4)U/A [19]. We next immuno-
precipitated (IP) hnRNP K from SCA10 and normal fibroblasts
and determined the presence of intron 9 of the ATNX10 transcript
in the IP pellets. RT-PCR analysis of the IP pellets showed the
presence of the intron 9 sequence of the ATXN10 transcript when
hnRNP K was precipitated from SCA10 fibroblasts but not from
normal fibroblasts (Figure 3C). We did not detect the presence of
exon 9 or exon 10 in the pellets, further corroborating the idea
that intron 9 containing the expanded AUUCU repeat is spliced
from the ATXN10 transcript. These data indicate that hnRNP K is
tightly associated with the expanded AUUCU repeat within the
intron 9 sequence in SCA10 cells.
To demonstrate the in vivo interaction of the expanded repeat
with hnRNP K, we investigated the co-localization of hnRNP K
with AUUCU RNA in transgenic mouse brain. The expanded
AUUCU repeat aggregates were visualized by FISH, and hnRNP
K was detected with anti-hnRNP K antibody by immunofluores-
cence. Sagittal sections of hippocampus CA1 (Figure 3E) and
cerebral cortex (Figure S3) from the 6-month-old transgenic mice
showed distinct co-localization of ,500 AUUCU aggregates with
endogenous hnRNP K. In contrast, control mouse brains showed
no foci (Figure 3D). We next transfected Sy5y cells with two
plasmids: one to express the ,500 AUUCU repeat (Figure 1C)
and the other to express GFP-tagged hnRNP K. FISH analysis of
the double-transfected cells revealed significant co-localization of
the red fluorescence from the AUUCU RNA repeat and the green
fluorescence from the GFP-hnRNP K (Figure 3F; arrow),
indicating that hnRNP K exists as a RNA-protein complex with
AUUCU RNA in vivo.
We assessed whether binding of hnRNP K with the expanded
AUUCU RNA interferes with hnRNP K activity by studying
hnRNP K-regulated alternative splicing of transcripts. hnRNP K
is known to regulate alternative splicing of exon 6A and 6B, the
mutually exclusive exons of the b-tropomyosin gene in vertebrates,
and decreased hnRNP K activity has been shown to increase the
inclusion of exon 6A and the exclusion of exon 6B [20,21]. RT-
PCR analysis showed that exon 6A is predominantly included in
the mature b-tropomyosin transcripts in SCA10 cells compared to
normal control cells (Figure 3G), suggesting that the hnRNP K
activity is decreased in SCA10 cells. Consistent with these results,
splicing of b-tropomyosin was also markedly altered in normal
fibroblasts ectopically expressing expanded AUUCU repeats (data
not shown).
Down-regulation of hnRNP K activates apoptosis
To understand the possible pathogenicity of a loss of hnRNP K
function in SCA10, we treated Sy5y cells with four different
hnRNP K siRNA duplexes. The sequence that most significantly
and reproducibly decreased hnRNP K protein level was used at
Figure 2. Expanded AUUCU repeat induces apoptosis. (A) TUNEL
assay on Sy5y cells expressing ,500 intronic AUUCU repeats. (B) TUNEL
assay on Sy5y cells expressing 12 intronic AUUCU repeats. (C)
Percentage of cells undergoing apoptosis when 12 and ,500 intronic
AUUCU repeats are expressed (n=6; p,0.0002). (D) Bar diagram
showing Caspase-3 activities as relative fluorescent units (RFU) when
Sy5y cells express 12 and ,500 AUUCU intronic repeats (right bars)
repeat (*n=3, p,0.0001).
doi:10.1371/journal.pgen.1000984.g002
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PLoS Genetics | www.plosgenetics.org 4 June 2010 | Volume 6 | Issue 6 | e1000984Figure 3. Expanded AUUCU-RNA binds to hnRNP K. (A) PAGE showing the proteins pulled down from mouse brain extract with biotin-labeled
AUUCU-RNA. Lane 1: Molecular weight marker, Lane 2: Proteins bound to lacZ transcripts with 12 AUUCU repeats; Lane 3: Proteins bound to ,500
AUUCU repeats + lacZ transcripts. The unique protein band that was analyzed by mass spectrometry is marked with arrow. (B) Western blot analysis
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Western blot analysis showed that cells treated with 100 pM
hnRNP K siRNA had .50% reduction in hnRNP K protein
level, compared to that in cells treated with control siRNA
(Figure 4A). We detected no significant cell death up to 48 hours
after siRNA treatment, in accordance with previous studies
[22,23]. However, we observed a large number of dying cells
72 hours after transfection with the hnRNP K siRNA; in
contrast, cells treated with control siRNA did not show significant
cell death. Activation of cell death pathways in Sy5y cells
transfected with hnRNP K siRNA was verified by significant
caspase-3 activity (n=3, p,0.001) (Figure 4B), and increased
TUNEL-positive cells (n=6, p,0.0001) (Figure 4C), 72 hours
post-transfection. The concentration of hnRNP K siRNA
sufficient to activate caspase-3-mediated apoptosis at 72 hours
was 100 pM (n=3, p=0.0001) (Figure 4D). Thus, down-
regulation of hnRNP K activates caspase-3-mediated apoptosis
similar to that observed in cells expressing expanded AUUCU
repeats.
hnRNP K over-expression rescues AUUCU–mediated
apoptosis
Based on our data we postulated that an interaction of hnRNP
K with the AUUCU repeat results in a loss of function of hnRNP
K, leading to apoptotic cell death. We studied whether hnRNP
K over-expression rescues cells from apoptosis induced by
expanded AUUCU repeats. We established stably transfected
Sy5y cell lines over-expressing hnRNP K, and then transiently
transfected them with the plasmid shown in Figure 1C. Sy5y cells
stably expressing a control plasmid in lieu of hnRNP K
Figure 4. Targeted inactivation of hnRNP K triggers apoptosis whereas ectopic expression of hnRNP K rescues AUUCU–mediated
apoptosis. (A) Western showing hnRNP K levels in Sy5y cells 72 hours after trasfecting with control siRNA and with 100pmoles siRNA for hnRNP K. b-
actin control is shown. (B) Caspase-3 activity of Sy5y cells is shown as the relative fluorescent units, 48 and 72 hours after treatment with 100pmoles
sihnRNP K (*n=3, p,0.0001) and 72 hours after treatment with control siRNA. (C) TUNEL assay showing the percentage of Sy5y cells undergoing
apoptosis after treating with control and sihnRNP K (*n=6, p,0.0001). (D) Caspase-3 activities of Sy5y cells is shown as the relative fluorescent units
(RFU), after treating with either 100 pM (*n=3, p=0.0001) or 200pmoles sihnRNP K compared to 100pmoles control siRNA. (E) Caspase-3 activities of
Sy5y cells expressing ,500 AUUCU repeats (black); Sy5y cells expressing hnRNP K and ,500 AUUCU repeats (grey).
doi:10.1371/journal.pgen.1000984.g004
of hnRNP K extracted from the RNA-protein complex at increasing salt concentration. Purified hnRNP K was incubated with single-stranded
(AUUCU)15 RNA or control RNA {(UUUCC)3(CCCUU)3(UUUUC)3} before extraction. The top blot is hnRNP K extracted from (AUUCU)15 RNA-protein
complex and the bottom blot is the hnRNP K fractions extracted from hnRNP K-control RNA complex. (C) RT-PCR analysis of the RNA-Co-IP pellet from
normal (lane 1) and SCA10 fibroblast extract (lane 2). The pulled down IP from SCA10 fibroblast extract shows the presence of intron 9 sequence of
ATXN10 gene. M=1 kb DNA ladder. (D) FISH on the sagittal section of the wild type control mouse brain. (E) FISH showing co-localization of
endogenous hnRNP K (green) with AUUCU RNA (red) in sagittal sections of the SCA10 transgenic mouse brain expressing ,500 intronic AUUCU
repeats. (F) FISH on Sy5y cells showing co-localization of hnRNP K with expanded AUUCU repeats. Red fluorescence: AUUCU RNA; Green fluorescence:
GFP-tagged hnRNP K and Yellow/Orange fluorescence: Overlap of red and green fluorescence (arrow). (G) RT-PCR analysis of total RNA from normal
(lane 1) and SCA10 (lane 2) fibroblasts showing aberrant splicing of b-tropomyosin.
doi:10.1371/journal.pgen.1000984.g003
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were expressed. In contrast, ,50% over-expression of hnRNP K
(Figure 4E) decreased the expanded AUUCU repeat-induced
apoptosis by ,30%, and this decrease in apoptosis is
accompanied by reduced caspase-3 activity (n=3, p,0.05)
(Figure 4E). These data confirm our hypothesis that expanded
AUUCU repeats activate apoptosis by suppressing hnRNP K
function.
PKCd is accumulated within SCA10 and transgenic
mitochondria
In vivo studies have shown that hnRNP K and PKCd remain
constitutively bound together within the cell [24–27]. Studies also
showed that hnRNP K, when bound to nucleic acids, cannot be
phosphorylated and cannot interact with PKCd [25]. PKCd has
been implicated as an activator of apoptosis in many cell types,
including neurons [28,29]. Over-expression of PKCd has been
shown to activate apoptosis through a positive regulatory loop, in
which caspase-3 activates PKCd and activated PKCd cleaves
caspase-3 [30]. PKCd over-expression results in its translocation to
mitochondria, release of cytochrome c, and activation of caspase-3
[30–32]. Since binding of hnRNP K to the expanded AUUCU
repeat is expected to reduce the formation of the hetero-dimeric
complexes between hnRNP K and PKCd, and mimic PKCd over-
expression, we investigated the ramifications of hnRNP K
inactivation on sub-cellular localization of PKCd in SCA10
fibroblasts and transgenic mouse expressing ,500 AUUCU
repeats in brain.
We first investigated whether cellular localization of PKCd is
altered in SCA10 cells. PKCd was immunostained with green
fluorescence and mitochondria were identified using mitotracker
deep red 633. Immunostaining of the normal fibroblasts for
PKCd showed that PKCd is present in the cytoplasm and the
nucleus, but no significant PKCd localization in mitochondria
(Figure 5A). In contrast, PKCd significantly overlaps with
mitochondria in SCA10 fibroblasts as punctate staining around
the nucleus, suggesting that a significant portion of PKCd is
translocated into the mitochondria (Figure 5B). To further verify
that the interaction between hnRNP K and PKCd is diminished
in SCA10 fibroblasts, we immunoprecipitated hnRNP K from
normal and SCA10 fibroblasts and analyzed the relative
abundance of hnRNP K and PKCd in the IP by Western blot
analysis. The Western blot data show a significantly lesser
amount of PKCd in the IP from the SCA10 fibroblasts compared
to normal fibroblast (Figure S4A). These data support our
hypothesis that expanded AUUCU RNA interacts with hnRNP
K and this binding results in the release of PKCd, facilitating
translocation of PKCd to mitochondria in SCA10. To test that
PKCd is translocated to the mitochondria in SCA10 cells, we
analyzed the mitochondrial protein fractions from SCA10 and
control fibroblasts by Western blotting. Consistent with the
immuno-histochemical data, the Western blot data showed
elevated PKCd level in SCA10 mitochondria (Figure S4B).
Moreover, sagittal sections of transgenic mouse brain showed
similar mitochondrial localization of PKCd while negligible
mitochondrial localization of PKCd was seen in age-matched
wild-type mice (Figure 5C and 5D). We also analyzed fibroblasts
derived from patients with ataxia telangiectasia, and unlike
SCA10 fibroblasts, these fibroblasts did not show presence of any
detectable level of PKCd in mitochondria (data not shown),
suggesting the disease specificity of this mechanism in SCA10.
These results suggest that PKCd is translocated into the
mitochondria of SCA10 cells.
Down-regulation of hnRNP K or expression of AUUCU–
RNA in normal fibroblasts result in translocation and
accumulation of PKCd in mitochondria
To test the hypothesis that the interaction of AUUCU RNA
with hnRNP K leads to a loss function of hnRNP K, which then
results in translocation of PKCd into mitochondria, we transfected
normal fibroblasts with hnRNP K siRNA and studied the cellular
localization of endogenous PKCd. When hnRNP K is downreg-
ulated, a majority of PKCd was translocated to mitochondria and
a negligible amount of PKCd was detected outside mitochondria
(Figure 6A). In normal fibroblasts, or in fibroblasts treated with
control siRNA, most of the PKCd was detected within cytoplasm
and nuclei, with no detectable translocation to mitochondria
(Figure 6B). Importantly, downregulation of hnRNP K in normal
fibroblasts did not alter the steady state level of PKCd (Figure
S4C).
We also expressed ,500 AUUCU repeats in primary human
fibroblasts and studied the expression and cellular localization of
PKCd in these cells to investigate whether AUUCU RNA
interferes with the expression and/or subcellular localization of
PKCd. We found that the expression of PKCd remained unaltered
in cells expressing expanded AUUCU repeats and the red
fluorescence from mitochondria significantly overlaps with the
green fluorescence from PKCd in fibroblasts expressing ,500
Figure 5. PKCd is localized in mitochondria in SCA10 fibro-
blasts and transgenic mouse brain. (A) PKCd (green) and
mitochondria (red) in control normal fibroblasts. (B) PKCd (green) in
SCA10 fibroblast (punctate aggregates), primarily outside nuclei. Merge
green (PKCd with red (mitochondria) iss e e na sy e l l o w / o r a n g e
fluorescence. (C) PKCd (green) and mitochondria (red) in the cortex of
the control transgenic mouse brain expressing 12 ATTCT repeats. (D)
PKCd (green) and mitochondria (red) in SCA10 transgenic mouse cortex
expressing ,500 AUUCU repeats. Merge of green (PKCd) and red
(mitochondria) is shown as yellow/orange fluorescence in cortex of the
SCA10 transgenic mice.
doi:10.1371/journal.pgen.1000984.g005
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expressing ,200 AUUCU repeats (Figure S5), suggesting that
PKCd translocates to mitochondria in response to the expression
of expanded AUUCU repeats. In contrast, a negligible transloca-
tion of PKCd was observed when 12 AUUCU repeats were
expressed in fibroblasts (Figure 6D). Together, these data
corroborate our hypothesis that the expanded AUUCU repeat
interacts with hnRNP K, suppresses its function, resulting in
mitochondrial translocation of PKCd and activation of apoptosis.
Targeted inactivation of ATXN10 transcripts in SCA10
cells reduces mitochondrial accumulation of PKCd
To test whether mitochondrial localization of PKCd can be
decreased by reducing the mutant ATXN10 transcript, we targeted
the ATXN10 transcript in SCA10 fibroblasts with two different
ATXN10 siRNA and studied the cellular localization of PKCd.
This resulted in significant decrease in the number of both nuclear
and cytoplasmic AUUCU RNA aggregates (Figure 7A; left panel),
whereas control siRNA did not reduce the number of AUUCU
RNA foci in SCA10 fibroblasts (Figure 7A; right panel). Treatment
of SCA10 fibroblasts with ATXN10 siRNA substantially restored
normal PKCd subcellular localization, with decreased amount in
mitochondria (Figure 7B; top panel). As expected, Control siRNA
had no significant effects on the distribution or amount of PKCd in
SCA10 cells (Figure 7B; center panel). Treatment of normal
fibroblasts with ATXN10 siRNA did not have any effect on PKCd
cellular localization (Figure 7B; bottom panel). We conclude that by
disrupting the hnRNP K-AUUCU complexes, hnRNP K can re-
establish its normal function within the cell, alleviating the
pathogenic mechanisms leading to apoptosis. These findings
support our hypothesis that expanded AUUCU repeats are toxic
and are sufficient to trigger PKCd translocation to mitochondria
and apoptosis.
Figure 6. Targeted inactivation of hnRNP K in normal fibro-
blasts or expression of expanded AUUCU-RNA results in
mitochondrial localization of PKCd. (A) PKCd (green) and
mitochondria (red) in normal fibroblasts transfected with sihnRNP K.
Merge of red and green fluorescence is seen as yellow/orange
fluorescence. (B) PKCd (green) and mitochondria (red) in normal
fibroblast treated with siControl.N o t ev e r yl i t t l ey e l l o w / o r a n g e
fluorescence. (C) PKCd (green) and mitochondria (red) in fibroblasts
expressing ,500 intronic AUUCU repeats. Co-localization of PKCd and
mitochondria is shown as yellow/orange fluorescence. (D) PKCd (green)
and mitochondria (red) in normal fibroblasts expressing 12 AUUCU
repeats from an intron. Bar represents 10 mm in (A–D).
doi:10.1371/journal.pgen.1000984.g006
Figure 7. Down-regulation of ATXN-10 in SCA10 fibroblasts
decreases PKCd localization in mitochondria. (A) FISH on SCA10
fibroblasts treated with siATXN10 (left) and with siControl (right). (B) Top
panel: PKCd (green) and mitochondria (red) in SCA10 fibroblasts
72 hours after treatment with siATXN10. Center panel: PKCd (green) and
mitochondria (red) in SCA10 fibroblasts, 72 hours after treating with
siControl, Bottom panel: PKCd (green) and mitochondria (red) in human
control fibroblasts. Bar represents 10 mm. (C) Schematic drawing
describing a probable mechanism for the diverse phenotypes
attributed with SCA10. The loss of hnRNP K function caused by the
binding of expanded AUUCU-RNA can trigger multiple aberrant
molecular signaling/processes in SCA10. Extensive neuronal loss may
results from the activation of caspase-3 and cleavage of PKCd triggering
neuronal death. In parallel, either loss or diminished function of hnRNP
K might result in aberrant splicing, transcription and translation of
multiple genes contributing towards the complex disease phenotypes
in SCA10.
doi:10.1371/journal.pgen.1000984.g007
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Multiple inherited human neurological disorders are now
attributed to expansion of short tandem repeats either in coding
or non-coding regions of genes [2,7,8]. Genetic and molecular
analysis of these disorders have revealed that the repeat expansion
can result in either a loss of function of the gene (Fragile-X
syndrome and Friedreich’s ataxia) or a gain of function of the
encoded protein (SCA1, SCA2, SCA3, SCA6, SCA7, SCA17,
Huntington’s disease, DRPLA, and oculopharyngeal muscular
dystrophy) [7,8]. RNA-mediated pathogenesis is believed to play a
critical role in several other repeat expansion disorders, including
Myotonic Dystrophy Type 1 (DM1) and Type 2 (DM2), SCA8,
SCA12, Huntington’s disease like 2 (HDL2), and fragile X tremor
ataxias syndrome (FXTAS) [7,8]. However, the pathogenic
mechanism of DM1, SCA8, SCA12, HDL2 and FXTAS, which
are caused by trinucleotide repeat expansions, may also involve
qualitative or quantitative alterations of the protein products of the
respective genes or genes on the opposite strand [33–35]. In
contrast, SCA10 is the only human disorder proven to be caused
by an expansion of a pentanucleotide repeat. Like the DM2
CCTG tetranucleotide repeat, the SCA10 ATTCT repeat shows
repeat-number polymorphism, which makes these non-trinucleo-
tide repeat highly unlikely to encode protein sequences from either
strand. Furthermore, we have shown that the intronic repeat
expansion does not alter ATXN10 transcripts [17]. Thus, SCA10
is likely to be a disorder solely caused by RNA-based mechanism,
unlike most disorders that are caused by trinucleotide repeat
expansions.
In the present study we provide evidence that SCA10
pathogenesis results from a trans-dominant gain-of-function of
AUUCU repeats. First, transcription of the mutant allele produces
transcripts that form aggregates in the nucleus and cytoplasm of
the SCA10 cells and in transgenic mouse brain. Second: the
expanded AUUCU repeat complexes with hnRNP K, leading to
the loss of function of hnRNP K. Third, expression of expanded
AUUCU repeat results in the accumulation of PKCd in the
mitochondria and caspase-3 mediated activation of apoptosis.
Fourth, diminished hnRNP K activity recapitulates these events
caused by expanded AUUCU repeats. And finally, over-
expression of hnRNP K, as well as down-regulation of transcripts
of expanded ATTCT repeat, rescues cells from apoptosis caused
by expanded AUUCU repeats. Based on these findings, we
conclude that the AUUCU RNA binds to and inactivates hnRNP
K, triggering caspase-3-mediated apoptosis via translocation of
PKCd to mitochondria. Previous reports suggest that the presence
of PKCd in the mitochondria results in decreased membrane
potential, release of cytochrome C, and activation of caspase-3
[30–32], further supporting our conclusion. Moreover, caspase-3
activates PKCd and activated PKCd further activates caspase-3
[30], and proteolytically activated PKCd down-regulates hnRNP
K protein in a proteasome-dependent manner [36]. Hence,
positive feedback loops involving hnRNP K, PKCd and caspase-3
may enhance this pathogenic pathway in SCA10. Since apoptosis
is considered to be a major mechanism of cell death in a variety of
human neurodegenerative disorders [37], the novel pathway of
apoptosis induced by the mutant ATXN10 RNA is relevant to the
neurodegenerative phenotype of SCA10. Our results provide
strong evidence that this novel mechanism of trans-dominant
RNA gain of function contributes to the pathogenic mechanism in
SCA10.
The formation of aggregates may not necessarily be a required
event for the mutant RNA to exert its toxicity. Binding of the
soluble form of the mutant RNA to hnRNP K may be sufficient to
cause the loss of function of hnRNP K with a release of PKCd,
and the aggregate formation could be a secondary phenomenon.
We hypothesize that expanded AUUCU RNA pathologically
binds to hnRNP K and prevents PKCd from binding to the
hnRNP K, mimicking over-expression of PKCd within the cell.
Previous studies have shown that hnRNP K is constitutively bound
to PKCd, but upon binding to nucleic acids, hnRNP K can no
longer interact with PKCd [25,30]. Translocation of PKCd to
mitochondria in SCA10 cells, fibroblasts expressing expanded
AUUCU repeat, and fibroblasts treated with hnRNP K siRNA
argues for this mechanism. Studies have shown multiple apoptotic
activators, including oxidative stress and over-expression of PKCd,
induce PKCd translocation to the mitochondria, [32]. The
mitochondrial translocation of PKCd has been shown to cause
an alteration in calcium signaling events and mediates the H2O2-
mediated loss of membrane potential, release of cytochrome c, and
activation of caspase-3 [38]. While it is possible that the expanded
AUUCU repeat causes PKCd translocation via other mechanisms,
our data showing that over-expression of hnRNP K rescues
AUUCU-mediated apoptosis argue for the mechanism mediated
by a loss of function of hnRNP K.
Our present data do not rule out the possibility that additional
proteins interact with the mutant ATXN10 transcripts. Also,
expression of hnRNP K is ubiquitous within the cell, and
diminished hnRNP K could lead to altered regulation of
transcription, splicing and cell signaling, which may account for
the phenotypic variability in SCA10 as illustrated in Figure 7C.
We are investigating these mechanisms. However, our current
data convincingly show that the hnRNP K inactivation and PKCd
mitochondrial translocation are a key pathogenic pathway
mediating the RNA gain of toxic function in SCA10.
Materials and Methods
Cell culture
SCA10 fibroblasts were isolated from skin biopsy from a
Mexican-American SCA10 patient with ,2000 repeats and a
Brazilian SCA10 patient with ,1000 repeats under signed
informed consent approved by IRB at UTMB and the Ethics
Committee at Federal University of Parana. These human
fibroblasts Cells were cultured in MEM with Eagle-Earle salt
and 2 mM L-glutamine containing 15% fetal bovine serum and
antibiotic in 5% CO2 at 37uCi n7 5 c m
2 flasks. Human
neuroblastoma Sy5y cells were cultured at Ham’s F12K medium
with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium
bicarbonate, 15% horse serum, 2.5% fetal bovine serum in 5%
CO2 at 37uCi n7 5c m
2 flasks.
Construction of plasmids
The cytomegalo virus (CMV) promoter sequences in plasmid
pCDNA3.1-hygro-lacZ (Invitrogen) were replaced with the MfeI/
BamHI fragment of the human a-enolase promoter sequences
(,5.0 kb). The 2
nd intron of rabbit b-globin intron was cloned
downstream of the enolase promoter and upstream of the lacZ.
Expanded ATTCT repeats from the SCA10 hybrid cells [17] were
PCR amplified with forward primer 59-CCAAGGATG-
CAGGTGCCACAGCATCTC-39 and reverse primer: 59-
ATATGCATCCAGCTTCTGATTACATGGACT-39. A poly-
linker containing SwaI site was cloned into the MfeI site within the
b-globin intron. Subsequently, the DNA fragment containing the
ATTCT duplex was cloned into the SwaI site within the intron.
Presence of the expanded ATTCT sequences in the transgenic
plasmid was confirmed by digesting the plasmid DNA with NheI
and HindIII sites that flank the SwaI site, and by sequencing.
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E. coli SURE bacteria at 16uC to minimize the deletion of the
repeat sequences [39]. The transgenic plasmid DNA containing
the LacZ and ,500 ATTCT repeats was digested with MfeI and
NaeI, and digested DNA was electrophoresed on agarose gel. The
,10 kb DNA fragment containing the transgene was purified
from agarose gel using gel extraction kit (Qiagen). The cloned
ATTCT repeats under enolase promoter contain 650 bp of
upstream and 500 bp of downstream ATXN10 sequence in
addition to the ATTCT repeats. The control plasmids containing
the same ATXN10 flanking regions and 12 ATTCT repeats were
PCR amplified from a normal subject. The cDNA clones of
human hnRNP K was purchased from Open Biosystems, USA
and cloned in-frame into pCGFP-C1 (BD Biosciences, USA). For
construction of plasmid for stable expression of hnRNP K, the
ORF of the human hnRNP K was PCR-amplified from the pool
of human cDNA (Clonetech) with the following primer sets:
forward: 59-CTGATTGGTGTGCCCGTTTAATAA-39 and re-
verse: 59-CTCCTTCAGTTCTTCACTAGTC-39. The 1507 bp
PCR product was purified from agarose gel using gel extraction kit
(Qiagen) and the blunt-ended PCR product was cloned into the
EcoRV site in the mammalian expression vector pcDNA3.1-
Hygro(+) (Invitrogen) to generate recombinant plasmid pcDNA-
hnRNP K. The coding sequence of hnRNP K in recombinant
plasmid pcDNA-hnRNP K was sequenced to verify the proper
orientation and sequence integrity of hnRNP K.
Development of the transgenic mouse line expressing
500 AUUCU repeats in brain
The transgene containing 500 ATTCT repeats within an intron
(Illustrated in Figure 1C) was microinjected into the fertilized eggs
and transplanted into the uterus of pseudo-pregnant surrogate
mothers to obtain founder transgenic mice using standard
procedure at the UTMB transgenic core facility. Presence of the
transgene and the repeat in the transgenic founder mice were
confirmed by both Southern blot as well as repeat primed PCR
analyses. Animal experiments were performed under a protocol
approved by IACUC at UTMB.
Repeat-primed PCR and Southern blot analysis in
transgenic mice
Mouse genomic DNA was collected from tail samples, and
repeat-primed PCR and Southern blot analyses were performed as
previously described [40].
Identification of AUUCU–RNA–binding proteins
Plasmid pcDNA3.1 control as well as pcDNA-(ATTCT)n
(n=500) were first linearized with Bam HI and the linear plasmid
was in vitro transcribed with T7 RNA polymerase (Promega).
Biotinylated rCTP was mixed with other rNTPs during
transcription to incorporate the biotin-labeled rCTP into
(AUUCU)n RNA. Nuclear extracts from brain were made from
a 2 month old B6 mouse using NE-PER Nuclear and
Cytoplasmic Extract Reagent (Pierce) according to vendors
specification. The total protein mixture was incubated with
(AUUCU)n RNA at 4uC overnight, and the unbound proteins
were washed by using RNA washing buffer (0.5% NP- 40,
100 mM NaCl, 50 mM Tris-HCl) four times. The proteins that
remain bound to the magnetic beads after extensive washing
were extracted by boiling the magnetic beads in 1X SDS-PAGE
loading buffer. The extracted proteins were electrophoresed on
5–12% PAGE and proteins that appear as unique bands were
excised, digested with trypsin and then analyzed by MALDITOF
assay at Biomolecular Resource Facility Core at UTMB and the
sequence was identified by searching the rodent protein
database.
Immuno-precipitation (IP) and RNA Co-IP
The SCA10 and control normal fibroblasts were harvested and
washed with 1X PBS, lysed in 20 mM HEPES pH 7.4, 1 mM
EDTA, 100 mM NaCl, 1% NP-40, Leupeptin (10 mg/ml),
aprotinin (10 mg/ml), 20 mM b-glycero-phosphate, 20 mM NaF
and 1 mM Na Vanadate. hnRNP K was immuno-precipitated
using anti-hnRNP K antibody and the IP pellet was washed three
times in the lysis buffer, and bound proteins were eluted in SDS-
containing sample buffer and separated on SDS-PAGE. The
membrane was first immunoblotted with anti-hnRNP K antibody
and then with PKCd antibody. To detect the intron 9 sequences of
ATXN10 in the IP pellet, total RNA was extracted from the IP
pellets by phenol-chloroform extraction, and DNA contamination
was removed with TURBO DNAse Kit (Ambion). The cDNA
synthesis was carried out using 1 mg of total RNA using a RT-
PCR kit (BD Biosciences). The cDNA aliquots were quantified and
cDNA were used to detect the presence of intron 9 sequences of
ATXN10 transcripts by PCR, using the forward primer 59-
AAGGATCAGAATCCCTGGAA-3 and the reverse primer 59-
TCATTCTGCCATCTGTTTTC-39.
The alternative splicing of b-tropomyosin
Splice isoforms of b-tropomyosin mRNA were analyzed using
RT-PCR as previously described [20,21] with a set of three
primers; E5: 59-GCCATGAAGGATGAGGAGAA-39 (forward
primer), E6a: 59-CTGAGGTGGCCGAGAGGTAA-39 (reverse
primer to detect exon E6a) and E6b: 59-TAAATGTGGGGACC-
TAGAGG-39 (reverse primer to detect exon E6b).
Solution binding assays of hnRNP K with (AUUCU)15 RNA
1 mg of the Streptavidin-conjugated Dynabeads (Invitrogen)
was washed once with Solution A (100 mM NaOH, and 50 mM
NaCl) and twice with Solution B (100 mM NaCl). The magnetic
beads were next incubated in 50 ml of 2X incubation buffer
(10 mM Tris, pH 7.5; 1 mM EDTA; 2 M NaCl,) for
15 minutes. 1000 pmoles (50 ml) of biotinylated RNA [ei-
ther (AUUCU)15 or control RNA: (UUUCC)3(CCCUU)3
(UUUUC)3.] were added to the magnetic beads, incubated at
room temperature for 1 hour, and washed twice with 1X
incubation buffer. Five mg of purified hnRNP K were added to
the magnetic bead-RNA mixture and incubated in a binding
buffer (20 mM HEPES, pH 7.5; 10% glycerol; 1 mM DTT;
0.1 mM EDTA) at 4uC for overnight. The supernatant was
discarded and the magnetic beads were resuspended in binding
buffer (25 mM Tris, pH 7.5; 0.1 mM EDTA; 10 mM NaCl).
RNA-bound hnRNP K was next sequentially eluted with buffers
containing increasing NaCl concentrations. The eluted hnRNP
K protein fractions were analyzed on PAGE by Coomasie
staining and Western blotting.
Antibodies and western blots
Mouse monoclonal anti-hnRNP K was obtained from Acris
Antibodies GmbH. Monoclonal anti-PKCd (G-9) and Cyto-
chrome C Oxidase (COXII) antibodies were purchased from
Santa-Cruz Biotechnology. The Western blotting experiments
were done according to standard procedure and the target
proteins were detected using ECL Western kit (Amersham).
Expression levels of b-actin (Abcam) were used as controls for
protein loading.
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Cells were grown in chamber slides overnight prior to TUNEL
assay. TUNEL assay was performed according to vendor
instructions (Roche). Student’s t-test was used to calculate
statistical significance.
Caspase-3 assay
Caspase-3 assay was performed according to instructions
supplied by vendor (Calbiochem). P values were calculated using
student’s t-test.
Transfection
Sy5y cells were transfected with plasmids or siRNA by
Lipofectamine 2000 reagent (Invitrogen). For the targeted
inactivation of hnRNP K, the On-target-Plus siRNA duplexes were
purchased from Dharmacon. The control non-targeting siRNA
from Dharmacon was used as a negative control for all siRNA
experiments. Approximately 100 and 200 nmoles of the siRNA
pools were used for the targeted down-regulation of hnRNP K,
and different assays were applied 72 hours after the transfection.
Fibroblasts were transfected using the human dermal fibroblast
nucleofector kit for electroporation (Amaxa Corporation). Plas-
mids expressing either 12 or 500 ATTCT repeats were transfected
at 3 mg according to kit instructions, and siRNA (both hnRNP K
and ataxin 10) was transfected according to kit instructions. For
stable over-expression of hnRNP K in Sy5y cells, pcDNA-hnRNP
K was digested with MfeI and the linear plasmid DNA was
tranefected into Sy5y cells using Lipofectamin 2000 reagent
(Invitrogen), and the stable clones were selected with hygromycin
(300 mg/ml). Total protein was isolated from the stably
transfected cells and the hnRNP K expression level was analyzed
by Western blotting with the anti-hnRNP K antibody.
Fluorescent In Situ Hybridization (FISH)
RNA foci were detected using a Cy3-labeled (AGAAU)10 RNA
riboprobe. Slides were pre-hybridized at 65uC in RNA hybrid-
ization buffer for 1.5 hours. Slides were then hybridized overnight
in 250 ng (AGAAU)10/1 ml hybridization solution at 45uC. Slides
were rinsed with PBS three times and then extensively washed 4
times 5 minutes each to remove all non-specific binding probes.
Slides were then mounted with DAPI mounting medium.
FISH and Immunohistochemistry
Transgenic mice anesthetized with Avertin were perfused
through the aorta, first rinsing for 15 minutes with PBS and then
60 ml of fresh 4% Paraformaldehyde (PFA) in DEPC water. The
brain was carefully removed and stored in 4% PFA at 4uC with
gentle agitation overnight. Brain tissue was then placed in 30%
sucrose overnight. Mouse brains were fixed in paraffin and
sectioned sagittally. RNA foci were stained using a Cy3-labeled
(AGAAU)10 riboprobe. First, paraffin was removed from the brain
sections and slides were dehydrated with 70%, 95% and 100%
Ethanol in DEPC water, and washed using DEPC PBS. Following
FISH, hnRNP K was immunodetected. Sections were blocked
with DAKO antibody blocking solution (serum-free) and later
double stained with anti-hnRNP K 1:1000 in DAKO antibody
diluent. Goat anti-mouse 488 was used to identify hnRNP K and
slides were visualized using a Hamamatsu Camera Controller
using DP controller software in histopathology lab at UTMB.
Translocation of PKCd into mitochondria
Fibroblasts were transfected with plasmids pcDNA-(ATTCT)12,
pcDNA-(ATTCT)500, hnRNP K siRNA or control siRNA
through electroporation. Transfections were conducted in cham-
ber slides. Thirty-six hours after repeat transfection and 72 hours
after RNAi transfection, the cells were treated with mitotracker
deep red 633 (Invitrogen) at a concentration of 250 nM in cell
culture medium. Cells were incubated at 37uC for 30 minutes.
After washing the cells three times with PBS, cells were then fixed
with 4% PFA for 30 minutes at room temperature. Cells were
washed 3 times with PBS and stored in 70% Ethanol for up to
24 hours. Cells were blocked with DAKO antibody blocking
solution (serum-free) and later double stained with anti-PKCd
1:500 in DAKO antibody diluent. Goat anti-mouse 488 was used
to identify PKCd. Fluorescent photomicrographs were taken using
a Hamamatsu Camera Controller using DP controller software in
the histopathology core lab at UTMB.
The sagittal section of the transgenic brain was processed
according to the procedure described above and immuno-stained
with anti-PKCd and Cox II antibodies to detect mitochnodria and
PKCd respectively. The cytoplasmic, nuclear and mitochondrial
protein fractions from normal and SCA10 cells were isolated using
the mitochondria isolation kit and Sub-cellular Protein Fraction-
ation kits (Thermo Scientific-Pierce). The isolated proteins were
analyzed by Western blotting using anti-PKCd antibody.
Supporting Information
Figure S1 Mutant ATXN10 transcripts are deposited as
insoluble aggregates. (A) Aggregates in SCA10 fibroblasts
encoding ,1000 CUG repeats: FISH showing the nuclear and
cytoplasmic AUUCU-RNA aggregates (arrow) in SCA10 fibro-
blasts encoding ,1000 ATTCT repeats. (B) Aggregates in normal
human fibroblasts ectopically expressing transcripts containing
expanded AUUCU repeats: FISH showing SCA10-like aggregates
(arrow) in normal fibroblasts transfected with plasmid encoding
,500 ATTCT repeats as schematically shown in Figure 1C. (C)
Aggregates in transgenic mouse brain expressing ,500 AUUCU
repeats: Upper panel: FISH showing nuclear, perinuclear and
cytoplasmic AUUCU-RNA foci or aggregates in a 3 month old
transgenic mouse brain expressing ,500 intronic AUUCU repeats
from the transgene described in Figure 1C. Lower panel: Control
mouse brain expressing 12 AUUCU repeats.
Found at: doi:10.1371/journal.pgen.1000984.s001 (1.12 MB TIF)
Figure S2 Expanded AUUCU repeats induces apoptosis in
PC12 cells. (A) TUNEL assay on PC12 cells expressing ,500 and
12 intronic AUUCU repeats. (B) Percentage of cells undergoing
apoptosis when 12 and ,500 intronic AUUCU repeats are
expressed in PC12 cells (n=6; p,0.00032). (C) Bar diagram
showing Caspase-3 activities as relative fluorescent units (RFU)
when PC12 cells express 12 and ,500 AUUCU intronic repeats
(*n=4, p,0.0002).
Found at: doi:10.1371/journal.pgen.1000984.s002 (0.91 MB TIF)
Figure S3 hnRNPK co-localizes with the expanded AUUCU-
RNA in the transgenic cortex. FISH showing co-localization of
hnRNP K (green) with AUUCU RNA (red) in sagittal sections of
the SCA10 transgenic mouse cortex (3 month old) expressing
,500 intronic AUUCU repeats expressing from the transgene as
described in Figure 1C. Bars represent 10 mm.
Found at: doi:10.1371/journal.pgen.1000984.s003 (0.88 MB TIF)
Figure S4 Interaction and levels of hnRNP K and PKCd in
SCA10 cell models. (A) Interaction of hnRNP K with PKCd is
diminished in SCA10 cells: The Western blot showing PKCd and
hnRNP K levels in the IP from the SCA10 cells expressing ,2000
AUUCU repeats and normal fibroblasts expressing 12 AUUCU
repeats. (B) PKCd levels in the mitochondrial protein fractions in
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levels in normal (lane 1 and 2) and SCA10 mitochondria (Lane 3
and 4): Cytochrome C Oxidase II (COX II) was used as loading
control of the mitochondrial protein fractions. (C) Down-
regulation of hnRNP K does not alter the steady state level of
PKCd. Western blot showing PKCd levels in normal fibroblasts
(Lane 1) and fibroblasts treated with 100 pmoles (Lane 2) and 200
pmoles (Lane 3) of hnRNP K-siRNA. (D) Ectopic expression of
AUUCU repeats does not alter the steady state level of
endogenous PKCd. Western blot showing the steady state level
of PKCd in normal human fibroblasts (Lane 1) and in SCA10
fibroblasts expressing ,500 AUUCU repeats (Lane 2).
Found at: doi:10.1371/journal.pgen.1000984.s004 (0.12 MB TIF)
Figure S5 Expression of ,200 AUUCU repeats in normal
fibroblasts results in massive mitochondrial localization of PKCd.
FISH showing PKCd (green) and mitochondria (red) in normal
fibroblasts transfected with plasmid encoding ,200 ATTCT
repeats: Merge of red and green fluorescence from mitochondria
and PKCd respectively is seen as yellow/orange fluorescence.
Found at: doi:10.1371/journal.pgen.1000984.s005 (0.98 MB TIF)
Acknowledgments
TA’s work was mostly done at UTMB before he moved to University of
Florida.
Author Contributions
Conceived and designed the experiments: MCW RG MW SR HYZ PSS
TA. Performed the experiments: MCW RG WX SMM JGL TKH MW
SFE PSS TA. Analyzed the data: MCW RG WX SMM JGL TKH MW
SFE HAGT HYZ PSS TA. Contributed reagents/materials/analysis tools:
MCW RG WX SMM JGL TKH MW SR HAGT PSS TA. Wrote the
paper: MCW RG PSS TA.
References
1. Lin X, Ashizawa T (2003) SCA10 and ATTCT repeat expansion: clinical
features and molecular aspects. Cytogenet Genome Res 100: 184–188.
2. Ashizawa T (2006) Spinocerebellar ataxia type 10: a disease caused by an
expanded (ATTCT)n pentanucleotide repeat. In: Wells RD, Ashizawa T, eds.
Genetic instabilities and neurological diseases. Burlington: Academic Press. pp
433–446.
3. Rasmussen A, Matsuura T, Ruano L, Yescas P, Ochoa A, et al. (2001) Clinical
and genetic analysis of four Mexican families with spinocerebellar ataxia type 10.
Ann Neurol 50: 234–239.
4. Teive HA, Roa BB, Raskin S, Fang P, Arruda WO, et al. (2004) Clinical
phenotype of Brazilian families with spinocerebellar ataxia 10. Neurology 63:
1509–1512.
5. Grewal RP, Achari M, Matsuura T, Durazo A, Tayag E, et al. (2002) Clinical
features and ATTCT repeat expansion in spinocerebellar ataxia type 10. Arch
Neurol 59: 1285–1290.
6. Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, et al. (2000)
Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia
type 10. Nat Genet 26: 191–194.
7. Gatchel JR, Zoghbi HY (2005) Diseases of unstable repeat expansion:
mechanisms and common principles. Nat Rev Genet 6: 743–755.
8. Brouner JR, Willemsen R, Oostra BA (2009) Microsatellite repeat instability and
neurological disease. Bioessays 31: 71–83.
9. Pandolfo M (2008) Friedreich ataxia. Arch Neurol 65: 1296–1303.
10. Sato N, Amino T, Kobayashi K, Asakawa S, Ishiguro T, et al. (2009)
Spinocerebellar ataxia type 31 is associated with ‘‘inserted’’ penta-nucleotide
repeats containing (TGGAA)n. Am J Hum Genet 85: 544–557.
11. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, et al. (2001)
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
Science 293: 864–867.
12. Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, et al. (2003)
Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2.
Ann Neurol 54: 760–768.
13. Matsuura T, Fang P, Pearson CE, Jayakar P, Ashizawa T, et al. (2006)
Interruptions in the expanded ATTCT repeat of spinocerebellar ataxia type 10:
repeat purity as a disease modifier? Am J Hum Genet 78: 125–129.
14. Raskin S, Ashizawa T, Teive HA, Arruda WO, Fang P, et al. (2007) Reduced
penetrance in a Brazilian family with Spinocerebellar Ataxia Type 10. Arch
Neurol 64: 591–594.
15. Marz P, Probst A, Lang S, Schwager M, Rose-John S, et al. (2004) Ataxin-10,
the spinocerebellar ataxia type 10 neurodegenerative disorder protein, is
essential for survival of cerebellar neurons. J Biol Chem 279: 35542–35550.
16. Waragai, Nagamitsu M, Xu S, Li W, Lin YJ, et al. (2006) Ataxin 10 induces
neuritogenesis via interaction with G-protein beta2 subunit. J Neurosci Res 83:
1170–1178.
17. Wakamiya M, Liu Y, Schuster GC, Gao R, Xu W, et al. (2006) The role of
ataxin-10 in spinocerebellar ataxia type 10 pathogenesis. Neurology 67:
607–613.
18. Keren B, Jacquette A, Depienne C, Leite P, Durr A, et al. (2010) Evidence
against haploinsufficiency of human ataxin 10 as a cause of spinocerebellar
ataxia type 10. Neurogenetics 11: 273–274.
19. Thisted T, Lyakhov DL, Liebhaber SA (2001) Optimized RNA targets of two
closely related triple KH domain proteins, heterogeneous nuclear ribonucleo-
protein K and alphaCP-2KL, suggest distinct modes of RNA recognition. J Biol
Chem 276: 17484–17496.
20. Tsukahara T, Casciato C, Helfman DM (1994) Alternative splicing of b-
tropomyosin pre-mRNA: multiple cis-elements can contribute to the use of the
59 and 39 splice sites of the non-muscle/smooth muscle exon 6. Nucl Acids Res
22: 2318–2325.
21. Expert-Bezancon A, Le Caer JP, Marie J (2002) hnRNP K is a component of an
intronic splicing enhancer complex that activates the splicing of the alternative
exon 6A from chicken b-tropomyosin pre mRNA. J Biol Chem 277:
16614–16623.
22. Lynch M, Chen L, Ravitz MJ, Mehtani S, Korenblat K, et al. (2005) hnRNP K
binds a core polypyrimidine element in the eukaryotic translation initiation
factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic
transformation. Mol Cell Biol 25: 6436–6453.
23. Moumen A, Masterson P, O’Connor MJ, Jackson SP (2005) hnRNP K: an
HDM2 target and transcriptional coactivator of p53 in response to DNA
damage. Cell 123: 1065–1078.
24. Schullery DS, Ostrowski J, Denisenko ON, Stempka L, Shnyreva M, et al.
(1999) Regulated interaction of protein kinase C delta with the heterogeneous
nuclear ribonucleoprotein K protein. J Biol Chem 274: 15101–15109.
25. Bomsztyk K, Denisenko O, Ostrowski J (2004) hnRNP K: one protein multiple
processes. Bioessays 26: 629–638.
26. Idriss H, Kumar A, Casas-Finet JR, Guo H, Damuni Z, et al. (1994) Regulation
of in vitro nucleic acid strand annealing activity of heterogeneous nuclear
ribonucleoprotein protein A1 by reversible phosphorylation. Biochemistry 33:
11382–11390.
27. Ostrowski J, Klimek-Tomczak K, Wyrwicz LS, Mikula M, Schullery DS, et al.
(2004) Heterogeneous nuclear ribonucleoprotein K enhances insulin-induced
expression of mitochondrial UCP2 protein. J Biol Chem 279: 54599–54609.
28. Kaasinen SK, Goldstein G, Alhonem L, Janne J, Koistinaho J (2002) Induction
and activation of protein kinase d in Hippocampus and Cortex after kainic acid
treatment, Exp Neurol 176: 203–212.
29. Nitti M, Furtaro AL, Traverso N, Odetti P, Storace D, et al. (2007) PKC delta
and NADPH oxidase in AGE-induced neuronal death. Neurosci Lett 416:
261–265.
30. Voss OH, Kim S, Wewers MD, Doseff AI (2005) Regulation of monocyte
apoptosis by the protein kinase Cdelta-dependent phosphorylation of caspase-3.
J Biol Chem 280: 17371–17379.
31. Brodie C, Blumberg PM (2003) Regulation of cell apoptosis by protein kinase c
delta. Apoptosis 8: 19–27.
32. Majumder PK, Pandey P, Sun X, Cheng K, Datta R, et al. (2000) Mitochondrial
translocation of protein kinase C delta in phorbol ester-induced cytochrome c
release and apoptosis. J Biol Chem 275: 21793–21796.
33. Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, et al. (2009) RNA
gain-of-function in spinocerebellar ataxia type 8. PLoS Genet 5: e1000600.
doi:10.1371/journal.pgen.1000600.
34. Rudnicki DD, Holmes SE, Lin MW, Thornton CA, Ross CA, et al. (2007)
Huntington’s disease–like 2 is associated with CUG repeat-containing RNA foci.
Ann Neurol 61: 272–82.
35. Oostra BA, Willemsen R (2009) FMR1: a gene with three faces. Biochim
Biophys Acta 1790: 467–77.
36. Gao FH, Wu YL, Zhao M, Liu CX, Wang LS, et al. (2009) Protein Kinase C-
delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K
protein: Involvement in apoptosis induction. Exp Cell Res 315: 3250–3258.
37. Jellinger KA, Stadelmann CH (2000) The enigma of cell death in
neurodegenerative disorders. J Neural Transm Suppl 60: 21–36.
38. Sumitomo M, Ohba M, Asakuma J, Asano T, Kuroki T, et al. (2002) Protein
kinase Cdelta amplifies ceramide formation via mitochondrial signaling in
prostate cancer cells. J Clin Invest 109: 827–836.
39. Sarkar PS, Chang HC, Boudi FB, Reddy S (1998) CTG repeats show bimodal
amplification in E. coli Cell 95: 531–540.
40. Matsuura T, Ashizawa T (2002) Polymerase chain reaction amplification of
expanded ATTCT repeat in spinocerebellar ataxia type 10. Ann Neurol 51:
271–272.
RNA Gain of Function in the Pathogenesis of SCA10
PLoS Genetics | www.plosgenetics.org 12 June 2010 | Volume 6 | Issue 6 | e1000984